Konieczkowski DJ, Garraway LA. Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones. Cell Res. 2013;23(1):13-4. doi:10.1038/cr.2012.115
Waldron L, Ogino S, Hoshida Y, et al. Expression profiling of archival tumors for long-term health studies. Clin Cancer Res. 2012;18(22):6136-46. doi:10.1158/1078-0432.CCR-12-1915
Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207-15. doi:10.1016/j.chom.2013.07.007
Hanna MC, Go C, Roden C, et al. Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One. 2013;8(9):e74950. doi:10.1371/journal.pone.0074950
Nan H, Morikawa T, Suuriniemi M, et al. Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst. 2013;105(24):1852-61. doi:10.1093/jnci/djt331
Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014;15(3):317-28. doi:10.1016/j.chom.2014.02.007
Younger ST, Rinn JL. ’Lnc’-ing enhancers to MYC regulation. Cell Res. 2014;24(6):643-4. doi:10.1038/cr.2014.54
Giannakis M, Hodis E, Mu XJ, et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet. 2014;46(12):1264-6. doi:10.1038/ng.3127
Wang S, Li N, Yousefi M, et al. Transformation of the intestinal epithelium by the MSI2 RNA-binding protein. Nat Commun. 2015;6:6517. doi:10.1038/ncomms7517
Ahronian LG, Sennott EM, Van Allen EM, et al. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov. 2015;5(4):358-67. doi:10.1158/2159-8290.CD-14-1518